Factors Contributing to Exacerbating Vulnerabilities in Global Clinical Trials

Area of Science:

• Clinical research ethics
• Global health policy
• Vulnerable populations in research

Background:

• Policies often use the term 'vulnerable' without clear definitions, particularly in clinical trials.
• Emerging economies show significant growth in clinical trials, necessitating robust oversight.
• The European Union's directive lacks specific reasoning for designating certain groups as vulnerable.

Purpose of the Study:

• To analyze characteristics of clinical trials involving vulnerable populations.
• To compare vulnerable populations across different development statuses and geographic regions.
• To identify factors contributing to vulnerability designations in international clinical trials.

Main Methods:

• Retrospective analysis of International Clinical Trials Registry Platform (ICTRP) data (2014).
• Selection of countries based on trial density, growth rate, and capabilities.
• Statistical analysis to identify factors associated with vulnerable patient classification.

Main Results:

• Patients incapable of personal consent were 11.4 times more likely to be deemed vulnerable.
• Patients in upper-middle-income countries were 1.7 times more likely to be vulnerable than those in high-income countries.
• Malaysia, Egypt, Turkey, Israel, and Brazil showed high percentages of pediatric vulnerable populations.

Conclusions:

• Inability to consent is a factor, but vulnerability criteria may be applied arbitrarily.
• Clearer guidance is needed from regulatory bodies like the EU Clinical Trials Register.
• Standardized criteria are essential to avoid misapplication of 'vulnerable' status in clinical research.